Citigroup Maintains Buy on Axsome Therapeutics, Lowers Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang maintains a Buy rating on Axsome Therapeutics (AXSM) but lowers the price target from $127 to $125.

May 07, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on Axsome Therapeutics but lowers the price target from $127 to $125.
The adjustment in price target by Citigroup reflects a slight modification in valuation expectations for Axsome Therapeutics, likely due to updated analysis or market conditions. However, maintaining a Buy rating indicates a continued positive outlook on the company's prospects. The impact on the stock price may be neutral to slightly positive as the reduction in target price is minimal and the Buy rating is reaffirmed, suggesting confidence in the company's fundamentals.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100